Final overall survival from a phase 3 trial of <i>nab</i>-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma.

Evan M. Hersh, Axel Hauschild, Michael P. Brown et al.|Journal of Clinical Oncology|2014

Cited by 5